Related Experiment Video

Updated: May 4, 2026

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection
10:25

"Liver-on-a-Chip" Cultures of Primary Hepatocytes and Kupffer Cells for Hepatitis B Virus Infection

Published on: February 19, 2019

13.1K

Low frequency of HLA-DRB1*11 in hepatitis C virus induced end stage liver disease

H L Tillmann1, D F Chen, C Trautwein

  • 1Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, Germany.

Gut
|April 17, 2001
PubMed

Insights

Certain human leucocyte antigen (HLA) alleles, specifically HLA-DRB1*11 and HLA-DQB1*03, are associated with a reduced risk of developing end-stage liver disease from Hepatitis C virus (HCV) infection.

Area of Science:

  • Immunogenetics
  • Hepatology
  • Virology

Background:

  • Hepatitis C virus (HCV) infection frequently leads to chronic liver disease and end-stage liver disease.
  • Host immune factors, including human leucocyte antigens (HLAs), may influence HCV infection outcomes.
  • Previous studies on HLA associations with HCV infection have yielded inconsistent results.

Purpose of the Study:

  • To investigate the association between HLA antigen phenotypes and the progression of HCV-induced liver cirrhosis.
  • To identify specific HLA alleles that may confer protection against the development of end-stage liver disease in HCV patients.

Main Methods:

  • Phenotype frequencies of HLA antigens were analyzed in two groups of patients with HCV-induced liver cirrhosis.
  • The first group (n=69) was serologically typed and compared to blood and liver donors (n=331).
  • The second group (n=39) underwent polymerase chain reaction-sequence specific oligonucleotide (PCR-SSO) typing for HLA-DRB and DQB alleles and was compared to 170 randomly selected blood donors.

Main Results:

  • Decreased frequencies of serological HLA-DR5 and HLA-DQ3 were observed in one patient group with HCV-induced liver cirrhosis.
  • Analysis of the second group confirmed a significant decrease in HLA-DRB1*11 and HLA-DQB1*03 alleles, corresponding to HLA-DR5 and HLA-DQ3.
  • These specific alleles were associated with a reduced risk of developing end-stage liver disease in HCV patients.

Conclusions:

  • The presence of HLA-DRB1*11 and HLA-DQB1*03 alleles is linked to a lower risk of developing end-stage liver disease caused by HCV.
  • These findings highlight the role of specific host genetic factors in modulating HCV disease progression.
  • Further research into HLA associations could inform personalized risk assessment and management strategies for HCV patients.

More Related Videos

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix10:37

Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix

Published on: October 20, 2021

2.4K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.5K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
28
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to...
42